

Alison Y Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3306627/publications.pdf>

Version: 2024-02-01

8
papers

1,665
citations

1307594

7
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

2381
citing authors

#	ARTICLE	IF	CITATIONS
1	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	27.0	982
2	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 797-804.	13.7	552
3	Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 949-962.	3.4	65
4	Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 385-393.	2.3	25
5	Recurrent Symptoms after Fundoplication with a Negative pH Study—Recurrent Reflux or Functional Heartburn?. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 54-60.	1.7	19
6	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. <i>International Journal of Cancer</i> , 2019, 144, 1151-1159.	5.1	13
7	CYSTIC TERATOMA OF THE PANCREAS: A RARE ENTITY. <i>ANZ Journal of Surgery</i> , 2008, 78, 1130-1131.	0.7	8
8	Racial disparity in metastatic renal cell cancer: The pharmacoeconomics and anthropology of sunitinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 197-199.	1.1	1